Antiphospholipid syndrome (APS) is a leading acquired cause of thrombotic events, with a
notable tendency to promote thrombosis in vascular beds of all sizes, including both arterial …

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by recurrent
arteriovenous thrombosis and pathological pregnancy, accompanied by persistent …

Background & aims Nonselective β blockers (NSBBs) facilitate the development of portal
vein thrombosis (PVT) in liver cirrhosis. Considering the potential effect of NSBBs on …

The onset of venous thromboembolism, including pulmonary embolism, represents a
significant health burden affecting more than 1 million people annually worldwide. Current …

Background Early exercise for acute deep venous thrombosis (DVT) improves the patient's
symptoms and does not increase the risk of pulmonary embolism. However, information …

Deep vein thrombosis (DVT) is a major cause of morbidity and mortality worldwide. Murine
models are critical tools for understanding the DVT mechanism and bridging the bench-to …

Aims To explore the effect of nonthrombotic internal jugular venous stenosis (IJVS) exerted
on cerebral venous thrombosis (CVT). Methods Patients with imaging confirmed CVT were …

Bleeding and thrombosis are major clinical problems with high morbidity and mortality.
Treatment modalities for these diseases have improved in recent years, but there are many …

Background The pathogenesis of deep vein thrombosis (DVT) is incompletely understood,
requiring reliable animal models. Inferior vena cava (IVC) stenosis model mimics human …

Portal vein thrombosis (PVT) refers to thromboembolism that occurs in the extrahepatic main
portal vein and/or intrahepatic portal vein branches. PVT is the result of the combined effect …